PROGEN Pharmaceuticals Limited has announced new preclinical data on PG545, a dual antiangiogenic and anti-heparanase inhibitor, will be presented at an international cancer therapeutics conference.
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Progen Pharmaceuticals (PGLA):